{"id":"gluteus-triamcinolone","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site pain or irritation"},{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Insomnia"},{"rate":null,"effect":"Mood changes"},{"rate":null,"effect":"Immunosuppression"}]},"_chembl":{"chemblId":"CHEMBL1200449","moleculeType":"Small molecule","molecularWeight":"478.51"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Triamcinolone exerts its anti-inflammatory effects through glucocorticoid receptor activation, which leads to decreased production of inflammatory mediators such as cytokines, chemokines, and adhesion molecules. When administered via gluteal intramuscular injection, it provides sustained local and systemic anti-inflammatory and immunosuppressive effects, making it useful for managing inflammatory and autoimmune conditions.","oneSentence":"Triamcinolone is a synthetic corticosteroid that suppresses inflammatory and immune responses by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:31:18.660Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Inflammatory and rheumatologic conditions requiring intramuscular corticosteroid therapy"},{"name":"Allergic and dermatologic disorders"}]},"trialDetails":[{"nctId":"NCT04002362","phase":"PHASE2","title":"Symptom Clusters in Children With Exacerbation-prone Asthma","status":"COMPLETED","sponsor":"Emory University","startDate":"2019-11-13","conditions":"Asthma in Children","enrollment":68},{"nctId":"NCT06456099","phase":"NA","title":"Feasibility of a Home Exercise Program With the Addition of a Corticosteroid Injection in Patients With Lateral Hip Pain","status":"RECRUITING","sponsor":"Aalborg University","startDate":"2024-06-07","conditions":"Greater Trochanteric Pain Syndrome","enrollment":20},{"nctId":"NCT05792111","phase":"PHASE4","title":"Caudal Epidural Steroid and Trigger Point Injection","status":"UNKNOWN","sponsor":"Abant Izzet Baysal University","startDate":"2022-10-12","conditions":"Myofascial Trigger Point Pain","enrollment":72},{"nctId":"NCT03407027","phase":"PHASE4","title":"Efficacy of Corticoid Infiltration in Quadratus Lumborum Syndrome","status":"UNKNOWN","sponsor":"Hospital de Braga","startDate":"2017-11-01","conditions":"Low Back Pain","enrollment":66},{"nctId":"NCT00798369","phase":"PHASE2","title":"Targeted Dose Finding of Canakinumab (ACZ885) for Management of Acute Flare in Refractory or Contraindicated Gout Patients","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-11","conditions":"Acute Gout","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["gluteus maximus infiltration with triamcinolone."],"phase":"marketed","status":"active","brandName":"Gluteus triamcinolone","genericName":"Gluteus triamcinolone","companyName":"Hospital de Braga","companyId":"hospital-de-braga","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Triamcinolone is a synthetic corticosteroid that suppresses inflammatory and immune responses by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production. Used for Inflammatory and rheumatologic conditions requiring intramuscular corticosteroid therapy, Allergic and dermatologic disorders.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}